{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:02:56Z","timestamp":1790744576642,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although next-generation sequencing (NGS) data on lymphomas require further validation before being implemented in daily practice, the clinical application of NGS can be considered right around the corner. The aim of our study was to validate an NGS lymphoid panel for tissue and liquid biopsy with the most common types of non-Hodgkin\u2019s lymphoma [follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)]. In this series, 372 somatic alterations were detected in 93.6% (44\/47) of the patients through tissue biopsy. In FL, we identified 93 somatic alterations, with a median of 7.4 mutations per sample. In DLBCL, we detected 279 somatic variants with a median of 8.6 mutations (range 0\u201335). In 92% (24\/26) of the cases, we were able to detect some variant in the circulating tumor DNA. We detected a total of 386 variants; 63.7% were detected in both types of samples, 13.2% were detected only in the circulating tumor DNA, and 23% were detected only in the tissue biopsy. We found a correlation between the number of circulating tumor DNA mutations, advanced stage, and bulky disease. The genetic alterations detected in this panel were consistent with those previously described at diagnosis. The liquid biopsy sample is therefore a complementary tool that can provide new genetic information, even in cases where a solid biopsy cannot be performed or an insufficient sample was obtained. In summary, we describe and analyze in this study the findings and difficulties encountered when incorporating liquid biopsy into clinical practice in non-Hodgkin\u2019s lymphoma at diagnosis.<\/jats:p>","DOI":"10.1038\/s41598-021-02362-4","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T11:02:33Z","timestamp":1637751753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin\u2019s lymphoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Mariana","family":"Bastos-Oreiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Su\u00e1rez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andr\u00e9s-Zayas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Carolina","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solsir\u00e9","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chicano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Diaz-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Menarguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Diez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Bu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mart\u00ednez-Laperche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"2362_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00277-020-03918-6","volume":"99","author":"M Bastos-Oreiro","year":"2020","unstructured":"Bastos-Oreiro, M. et al. RELINF: Prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. Ann. Hematol. 99, 799\u2013808 (2020).","journal-title":"Ann. Hematol."},{"key":"2362_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1365-2141.2003.04629.x","volume":"123","author":"JF Lester","year":"2003","unstructured":"Lester, J. F. et al. The clinical impact of expert pathological review on lymphoma management: A regional experience. Br. J. Haematol. 123, 463\u2013468 (2003).","journal-title":"Br. J. Haematol."},{"key":"2362_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore, A. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16, 1111\u20131122 (2015).","journal-title":"Lancet Oncol."},{"key":"2362_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"2362_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396\u20131407 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2362_CR6","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina, V. et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 131, 2413\u20132425 (2018).","journal-title":"Blood"},{"key":"2362_CR7","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.ctrv.2020.102106","volume":"91","author":"M Cirillo","year":"2020","unstructured":"Cirillo, M., Craig, A. F. M., Borchmann, S. & Kurtz, D. M. Liquid biopsy in lymphoma: Molecular methods and clinical applications. Cancer Treat. Rev. 91, 102106 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"2362_CR8","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer, F. et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci. Transl. Med. 8, 364ra155 (2016).","journal-title":"Sci. Transl. Med."},{"issue":"Suppl 1","key":"2362_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/hon.2587","volume":"37","author":"C Melani","year":"2019","unstructured":"Melani, C., Wilson, W. H. & Roschewski, M. Liquid biopsy in non-Hodgkin\u2019s lymphoma. Hematol. Oncol. 37(Suppl 1), 70\u201374 (2019).","journal-title":"Hematol. Oncol."},{"key":"2362_CR10","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz, G. et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. U. S. A. 105, 13520\u201313525 (2008).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2362_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12943-017-0580-4","volume":"16","author":"M Zhou","year":"2017","unstructured":"Zhou, M. et al. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Mol. Cancer 16, 16 (2017).","journal-title":"Mol. Cancer"},{"key":"2362_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet, S. et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 19, 549\u2013561 (2018).","journal-title":"Lancet Oncol."},{"key":"2362_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","volume":"131","author":"MR Green","year":"2018","unstructured":"Green, M. R. Chromatin modifying gene mutations in follicular lymphoma. Blood 131, 595\u2013604 (2018).","journal-title":"Blood"},{"key":"2362_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/15592294.2017.1282587","volume":"12","author":"K Korfi","year":"2017","unstructured":"Korfi, K., Ali, S., Heward, J. A. & Fitzgibbon, J. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Epigenetics 12, 370\u2013377 (2017).","journal-title":"Epigenetics"},{"key":"2362_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.beha.2017.10.006","volume":"31","author":"T Lackraj","year":"2018","unstructured":"Lackraj, T., Goswami, R. & Kridel, R. Pathogenesis of follicular lymphoma. Best Pract. Res. Clin. Haematol. 31, 2\u201314 (2018).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"2362_CR16","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/bloodadvances.2018023572","volume":"2","author":"LC Chong","year":"2018","unstructured":"Chong, L. C. et al. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv. 2, 2755\u20132765 (2018).","journal-title":"Blood Adv."},{"key":"2362_CR17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3324\/haematol.2018.190157","volume":"103","author":"ED McPhail","year":"2018","unstructured":"McPhail, E. D. et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements is not associated with MYC\/IG gene rearrangements. Haematologica 103, 1899\u20131907 (2018).","journal-title":"Haematologica"},{"key":"2362_CR18","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","volume":"131","author":"L Pasqualucci","year":"2018","unstructured":"Pasqualucci, L. & Dalla-Favera, R. Genetics of diffuse large B-cell lymphoma. Blood 131, 2307\u20132319 (2018).","journal-title":"Blood"},{"key":"2362_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","volume":"52","author":"L Pasqualucci","year":"2015","unstructured":"Pasqualucci, L. & Dalla-Favera, R. The genetic landscape of diffuse large B-cell lymphoma. Semin. Hematol. 52, 67\u201376 (2015).","journal-title":"Semin. Hematol."},{"key":"2362_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3324\/haematol.2018.206177","volume":"104","author":"D Rossi","year":"2019","unstructured":"Rossi, D., Spina, V., Bruscaggin, A. & Gaidano, G. Liquid biopsy in lymphoma. Haematologica 104, 648\u2013652 (2019).","journal-title":"Haematologica"},{"key":"2362_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","volume":"178","author":"DM Kurtz","year":"2019","unstructured":"Kurtz, D. M. et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 178, 699-713.e19 (2019).","journal-title":"Cell"},{"key":"2362_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/978-1-4939-8876-1_19","volume":"1881","author":"D Rossi","year":"2019","unstructured":"Rossi, D., Condoluci, A., Spina, V. & Gaidano, G. Methods for measuring ctDNA in lymphomas. Methods Mol. Biol. Clifton NJ 1881, 253\u2013265 (2019).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"2362_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11864-016-0425-1","volume":"17","author":"M Kwok","year":"2016","unstructured":"Kwok, M., Wu, S. P., Mo, C., Summers, T. & Roschewski, M. Circulating tumor DNA to monitor therapy for aggressive B-cell lymphomas. Curr. Treat. Options Oncol. 17, 47 (2016).","journal-title":"Curr. Treat. Options Oncol."},{"key":"2362_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JOP.19.00691","volume":"16","author":"S Huet","year":"2020","unstructured":"Huet, S. & Salles, G. Potential of circulating tumor DNA for the management of patients with lymphoma. JCO Oncol. Pract. 16, 561\u2013568 (2020).","journal-title":"JCO Oncol. Pract."},{"key":"2362_CR25","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz, D. M. et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 36, 2845\u20132853 (2018).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02362-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02362-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02362-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:24:38Z","timestamp":1670088278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02362-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2362"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02362-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22815"}}